Abstract Library

#4227 Evaluation of circulating extracellular vesicles as suitable prognostic markers in MEN1-associated non-functioning pancreatic neuroendocrine neoplasia

Introduction: Non-functioning pancreatic neuroendocrine neoplasias (NF-pNENs) significantly contribute to premature death of multiple endocrine neoplasia type 1 (MEN1) patients. Reliable prognostic markers for disease progression are lacking. Circulating liquid biomarkers, including microRNAs and Long-non-Coding (LnC) RNAs in extracellular vesicles, are emerging as new prognostic tools.

Conference:

Presenting Author:

Authors: Manoharan J, Khizanishvili N, Krasser-Gercke N, Albers M, Mintziras I,

Keywords: Multiple endokrine neoplasia type 1, Extracellular vesicles, Non-functioning pancreatic neuroendocrine neoplasia, exosomal-LnC-RNA NEAT1, exosomal miRNA451a,

#4046 A single institution experience of clinic-molecular characterisation and correlation with treatment outcomes in patients with advanced extrapulmonary high grade neuroendocrine carcinomas: The NIRVANA study

Introduction: The gene mutation profiles of extra-pulmonary (EP) neuroendocrine carcinomas (NECs) and mixed neuroendocrine / non-neuroendocrine carcinomas (MiNENs) are incompletely understood.

Conference:

Presenting Author: Spada F

Authors: Spada F, Pisa E, Ranghiero A, Frassoni S, Bagnardi V,

Keywords: NEC, MiNEN, NGS, KRAS, TP53, MSI, extra-pulmonary,

#3345 Integrative molecular analysis of combined small-cell lung carcinoma reveals EGFR and KRAS mutational analysis as the theragnostic tools in whole small cells lung carcinoma landscape

Introduction: Combined small-cell lung cancer (C-SCLC) are composed of SCLC admixed with a non-small-cell cancer component. They currently receive the same treatment as SCLC. The recent evidence that SCLC may belong to either of 2 lineages, neuroendocrine or non-neuroendocrine, with different vulnerability to specific cell death pathways such as ferroptosis, opens new therapeutic opportunities also for C-SCLC.

Conference:

Presenting Author:

Authors: Simbolo M, Centonze G, Ali G, Ciaparrone C, Grillo F,

Keywords: Combined small cell lung carcinoma, small cell lung cancer, neuroendocrine carcinoma, next generation sequencing, transcriptomics,

#3246 Baseline albumin and neutrophil-to-lymphocyte ratio as predictive biomarkers of response to platinum-based therapy in patients with highly proliferative neuroendocrine carcinomas

Introduction: Neuroendocrine carcinomas (NECs) with ki-67/MIB1>55% show different responses to platinum-based therapy. Loss of Rb protein and KRAS mutation are markers of response, but it is unknown whether also clinical factors may have a predictive role.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Colombo E

Authors: Colombo E, Manca P, Prinzi N, Torchio M, Corti F,

Keywords: neuroendocrine carcinoma, albumin, neutrophil-to-lymphocyte ratio, neutropenia, platinum-based therapy, predictive biomarker, clinical biomarker, NECs,

#2991 Gastroenteropancreatic (GEP) Neuroendocrine Neoplasia G3 (NEN G3) According to 2019 WHO Classification: A Comprehensive Clinicopathological Characterization Including Mismatch Repair (MMR) Proteins, PDL1 Expression and KRAS/BRAF Status

Introduction: In the 2019 WHO FOR NEN’S classification NETG3 have been distinguished from poorly differentiated neuroendocrine carcinoma (NEC). They are heterogeneous group concerning prognosis and treatment benefit.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Ruiz G, Graselli J, Golubicki M, Rizzol M,

Keywords: G3 NEN, PD-L1, KRAS, BIOMARKERS,